Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy A Greene

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|March 12, 2020
Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes TherapyMariana P Socal, Jeremy A Greene
The New England Journal of Medicine|March 19, 2015
Why is there no generic insulin? Historical origins of a modern problemJeremy A Greene, Kevin R Riggs
The New England Journal of Medicine|October 19, 2012
Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50Jeremy A Greene, Scott H Podolsky
The New England Journal of Medicine|August 20, 2015
The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of PharmaceuticalsJeremy A Greene, Elizabeth S Watkins
The New England Journal of Medicine|March 27, 2020
From Ariadne's Thread to the Labyrinth Itself - Nosology and the Infrastructure of Modern MedicineAnne Kveim Lie, Jeremy A Greene
The New England Journal of Medicine|June 8, 2017
Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging LawJeremy A Greene, William V Padula
The New England Journal of Medicine|November 26, 2010
Pharmaceutical marketing and the new social mediaJeremy A Greene, Aaron S Kesselheim
The Journal of Medical Humanities|August 7, 2014
Are the Medical Humanities for Sale? Lessons from a Historical DebateScott H Podolsky, Jeremy A Greene
American Journal of Public Health|May 18, 2013
The decline and rise of coronary heart disease: understanding public health catastrophismDavid S Jones, Jeremy A Greene
The New England Journal of Medicine|April 11, 2019
Preying on Prescribers (and Their Patients) - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler LegacyScott H Podolsky, David Herzberg, Jeremy A Greene
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|March 12, 2020
Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes TherapyMariana P Socal, Jeremy A Greene
The New England Journal of Medicine|March 19, 2015
Why is there no generic insulin? Historical origins of a modern problemJeremy A Greene, Kevin R Riggs
The New England Journal of Medicine|October 19, 2012
Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50Jeremy A Greene, Scott H Podolsky
The New England Journal of Medicine|August 20, 2015
The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of PharmaceuticalsJeremy A Greene, Elizabeth S Watkins
The New England Journal of Medicine|March 27, 2020
From Ariadne's Thread to the Labyrinth Itself - Nosology and the Infrastructure of Modern MedicineAnne Kveim Lie, Jeremy A Greene
The New England Journal of Medicine|June 8, 2017
Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging LawJeremy A Greene, William V Padula
The New England Journal of Medicine|November 26, 2010
Pharmaceutical marketing and the new social mediaJeremy A Greene, Aaron S Kesselheim
The Journal of Medical Humanities|August 7, 2014
Are the Medical Humanities for Sale? Lessons from a Historical DebateScott H Podolsky, Jeremy A Greene
American Journal of Public Health|May 18, 2013
The decline and rise of coronary heart disease: understanding public health catastrophismDavid S Jones, Jeremy A Greene
The New England Journal of Medicine|April 11, 2019
Preying on Prescribers (and Their Patients) - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler LegacyScott H Podolsky, David Herzberg, Jeremy A Greene
Pageof 8